Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Dana Pe'er is a Professor and Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) of Memorial Sloan Kettering Cancer Center. She is also an Investigator of the Howard Hughes Medical Institute and holds the Alan and Sandra Gerry Endowed Chair. Dr. Pe'er leads an interdisciplinary research group that combines advanced genomics approaches with machine learning to address fundamental questions in biomedical science, with particular focus on cancer biology, developmental biology, and immunology. Dr. Pe'er earned her PhD from Hebrew University in Jerusalem, Israel. Her academic journey includes a postdoctoral fellowship with George Church at Harvard Medical School. Before joining Memorial Sloan Kettering Cancer Center in 2016, she held faculty positions at Columbia University. Dr. Pe'er's research focuses on understanding cellular plasticity, the consequences of intra-tumor heterogeneity, cancer evolution and metastasis, and the mechanisms by which regulatory circuits go awry in disease. Her lab combines single-cell and spatial profiling technologies with machine learning approaches to investigate gene regulation, cellular plasticity, and cell-cell communication in the contexts of cancer, immunity, and development. They are particularly interested in how organisms develop from a single cell to generate diverse cell types, how epigenetic control rewires during development, and how cells communicate to execute multicellular responses. Analysis of Dr. Pe'er's recent publications reveals a strong focus on developing computational methods for single-cell and spatial genomics data analysis. Her work spans cancer types including pancreatic, prostate, colorectal, and breast cancer, with emphasis on tumor heterogeneity, metastasis mechanisms, and cellular plasticity. A significant portion of her research involves creating novel algorithms and tools like CellRank, REUNION, and SEACells that enable researchers to extract meaningful biological insights from complex genomic datasets. 2023 Class of 2023 Inductee - American Academy of Cancer Research (AACR) Academy 2023 Innovator Award - International Society for Computational Biology (ISCB) 2021 Fellow - International Society for Computational Biology (ISCB) Howard Hughes Medical Institute Investigator (2021) 2019 Ernst W. Bertner Memorial Award - University of Texas MD Anderson Cancer Center 2016 Lenfest Distinguished Faculty Award - Columbia University 2014 Director's Pioneer Award - National Institutes of Health 2014 Overton Prize - International Society for Computational Biology (ISCB) Dr. Pe'er is known for her dedicated mentorship approach, describing herself as "a mama bear" who cares deeply about her trainees while expecting independence, innovation, and hard work. She mentors numerous PhD students and postdocs in her lab. Her HHMI Investigator award provides approximately $9 million over seven years, enabling ambitious research directions. She also collaborates extensively with the Single-cell Analytics and Innovation Lab (SAIL) at MSK to generate new data from emerging technologies, working closely with wet-lab collaborators at MSK and beyond to apply computational methods to cutting-edge datasets across multiple disease areas. The Pe'er Lab is an interdisciplinary group of computational biologists with diverse backgrounds ranging from pure mathematics to clinical medicine. They work closely with wet-lab collaborators to apply their computational methods to cutting-edge datasets across cancer, immunology, and developmental biology. The lab is described as open, supportive, collaborative, and fun, with access to world-class facilities at the Sloan Kettering Institute. Dr. Pe'er's work continues to push the boundaries of computational biology and cancer research, with the ultimate goal of developing more effective, personalized therapies for cancer patients.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Prashant Mali is a Professor in the Department of Bioengineering at the University of California, San Diego . His research bridges genome engineering, RNA biology, and biomedical applications, with a focus on CRISPR-Cas systems and ADAR-mediated RNA editing. Education : Ph.D. in Bioengineering Key Affiliations : UC San Diego, Altman Clinical and Translational Research Institute Dr. Mali's work centers on CRISPR-Cas9 technology , RNA editing , and human pluripotent stem cells . His lab develops tools for programmable gene regulation, synthetic lethal screens, and metabolic pathway analysis in disease contexts. Recent publications highlight innovations in circular RNA engineering , ADAR activity mapping , and metabolic reprogramming in cancer . His team employs multi-omics approaches and in vivo models to translate genome editing into clinical applications. Students and Collaborators Current Lab Members : Sami Nourreddine (Postdoc), Amir Dailamy (Graduate), Andrew Portell (Graduate), Michael Tong (Graduate) Alumni : Kyle Ford (PhD 2022), Nathan Palmer (PhD 2022), Udit Parekh (PhD 2021) Research Themes CRISPR Screens : Synthetic lethal interactions, oncogenic pathways, metabolic vulnerabilities RNA Editing : ADAR engineering, circular guide RNAs, clinical translation Tissue Engineering : Vascularized organoids, cardiac maturation, ex vivo models
Jude M. Phillip, PhD, is an Assistant Professor in the Departments of Biomedical Engineering and Chemical and Biomolecular Engineering at Johns Hopkins University. His research integrates engineering principles with aging and cancer biology to develop cell-based biomarkers and mechanistic insights into age-related diseases. He leads the Phillip tiME Lab, which focuses on aging dynamics, tumor microenvironment interactions, and translational technologies. Education : PhD, Chemical and Biomolecular Engineering, Johns Hopkins University, 2015 Postdoctoral Research, Melnick/Cerchietti Labs, Weill Cornell Medicine, 2016-2020 B.Eng, Chemical Engineering, City College of New York, 2010 Research Interests : Dr. Phillip’s work spans aging mechanisms, cancer biology, and mechanobiology. Key areas include: Cell-based biomarkers for aging and disease Scale-dependent aging pathways Lymphoma tumor-immune microenvironment (tiME) Single-cell profiling of senescence subtypes ECM mechanoregulation of stem cell fate His lab employs longitudinal cell profiling, data science, and clinical measures to bridge biological aging research with translational medicine. Recent Highlights : 2025: NIH R35 MIRA Award for lymphoma microenvironment research 2024: Johns Hopkins Catalyst Award for aging biomarker studies 2023: AFAR-Glenn Foundation Award for senescence subtype classification Lab & Collaborations : The Phillip Lab collaborates with the Institute for NanoBioTechnology and maintains a living patient-derived tumor biorepository for lymphoma studies. Current projects include ovarian aging organoid models and immune-mechanical interactions in cancer progression.
Miler T. Lee is an Associate Professor at the University of Pittsburgh , focusing on gene regulation during early embryonic development through high-throughput experimental and computational genomics. He earned his Ph.D. in Genomics and Computational Biology in 2009 from the University of Pennsylvania under Dr. Junhyong Kim, followed by postdoctoral work with Dr. Antonio Giraldez at Yale University. Joining the university in 2016, his research spans maternal-to-zygotic transition (MZT), RNA stability, pluripotency networks, and evolutionary developmental biology, utilizing model organisms like zebrafish, Xenopus, and Hydractinia symbiolongicarpus. Key Research Themes: Maternally inherited RNA dynamics during embryogenesis Mechanisms of RNA degradation and transcriptome remodeling Evolution of pluripotency networks in hybrid species Role of zinc signaling in fertilization barriers Computational tools for RNA regulation and sensing Scientific Awards: Pan-American Society for Evolutionary Developmental Biology Junior Faculty Award (2024) Outstanding New Investigator – International Xenopus Board (2023) Basil O'Connor Scholar – March of Dimes (2017-2019) Recent publications highlight his work on enhancer classification, RNA degradation mechanisms, and cross-species MZT comparisons. His lab develops innovative methods like RESA for regulatory sequence analysis and studies evolutionary divergence in RNA localization patterns. While the articles span computational and experimental approaches, they consistently address RNA's role in cellular identity, developmental timing, and evolutionary adaptation. Applications include understanding pluripotency, designing RNA biosensors, and elucidating fertilization barriers. Prospective Ph.D. students are encouraged to contact him for opportunities in gene regulation, development, evo-devo, and computational genomics.
Joel Blanchard, PhD, is an Associate Professor in the Departments of Neuroscience and Cell, Developmental & Regenerative Biology at the Icahn School of Medicine at Mount Sinai. He is also an Investigator at the Black Family Stem Cell Institute and the Ronald Loeb Center for Alzheimer’s Disease. His research focuses on developing human brain models using induced pluripotent stem cells to study and treat neurodegenerative diseases. Education: BS, St. Lawrence University MLA, Harvard University PhD, The Scripps Research Institute & MIT Research Interests: Dr. Blanchard’s lab is dedicated to understanding the genetic and environmental vulnerabilities that lead to neurodegeneration. His team develops cutting-edge 3D brain organoids and blood-brain barrier models to investigate diseases like Alzheimer’s, Parkinson’s, and ALS. A major focus is on the role of APOE4 in myelination, cholesterol metabolism, and vascular dysfunction. Scientific Awards: Friedman Brain Institute Scholar Award (2021) ISSCR Merit Award (2019) Glenn Foundation Postdoctoral Fellowship (2018) California Institute for Regenerative Medicine Pre-doctoral Fellowship (2011) Funding & Grants: Dr. Blanchard’s lab is currently funded by NASA, NIH, and the Cure Alzheimer’s Fund. Active projects include the development of miBrain (multicellular integrated brain tissue), blood-brain barrier modeling, and APOE4-mediated mechanisms of neurodegeneration. Lab & Team: The Blanchard Lab is a multidisciplinary team of postdocs, graduate students, and research associates. The lab is actively recruiting postdoctoral fellows and is known for its collaborative, innovative environment focused on translational neuroscience.
Dana Pe'er is Chair of the Computational and Systems Biology Program at the Sloan Kettering Institute (SKI) and an Investigator at the Howard Hughes Medical Institute (HHMI). She holds the Alan and Sandra Gerry Endowed Chair and leads an interdisciplinary lab combining single-cell genomics, machine learning, and computational modeling to study cancer biology, immunity, and development. Pe'er earned her PhD at the Hebrew University in Jerusalem and focuses on cellular plasticity, epigenetic regulation, and tumor-immune interactions. Her lab develops tools like CellRank , Wishbone , and SEACells to analyze single-cell data and uncover mechanisms in cancer progression and immunotherapy. Key research areas: Computational Biology, Single-Cell Genomics, Cancer Systems Biology, Epigenetics, Immunotherapy Recent trends: Articles from 2025-2024 emphasize spatial transcriptomics, tumor microenvironment mapping, and regulatory network inference using machine learning. Scientific honors include the NIH Director’s Pioneer Award , AACR Academy Induction , and Packard Fellowship . Her work has direct clinical implications for precision medicine and cancer immunotherapy. Labs & Teams: Leads the Dana Pe'er Lab at SKI, directs the Single Cell Research Initiative (SCRI), and collaborates with the SAIL program.
Dr. Jun Wu is an Assistant Professor in the Department of Molecular Biology at UT Southwestern Medical Center. He holds a PhD in Life Science from the University of Tennessee and completed postdoctoral training at the University of Southern California and the Salk Institute. His research focuses on stem cell biology, genome editing, and interspecies chimeras to advance regenerative medicine and developmental biology. Education: Bachelor of Medicine, Shandong University School of Medicine (China) PhD in Life Science, University of Tennessee (2013) Postdoctoral Fellowships: USC (2013-2015) and Salk Institute (2015-2017) Research Interests: Generation of pluripotent stem cells with distinct molecular/phenotypic features Development of interspecies blastocyst complementation systems Modeling peri-implantation human development using stem cell embryo models Study of species-specific developmental barriers and evolutionary biology Application of chimeras to study cancer resistance and organ size determination Lab Activities: The Wu Lab develops stem cell models to study mammalian development and create regenerative therapies. Key projects include: Creation of interspecies chimeras (human-monkey, rat-mouse) Development of blastoids and peri-gastruloids Analysis of species-specific cell competition mechanisms Engineering cross-species organogenesis systems Grant Activities: Focuses on NIH-funded projects related to stem cell biology, interspecies chimerism, and regenerative medicine applications. Collaborates with institutions like Salk Institute and University of California campuses. Lab Team: Includes postdoctoral researchers like Dr. Yi Ding and a multidisciplinary team of molecular biologists, bioengineers, and computational biologists.
Hokyung Kay Chung, PhD is an Assistant Professor in the Department of Cell Biology and Physiology at the University of North Carolina at Chapel Hill School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center. Her research program integrates synthetic biology, immunology, and cancer biology to engineer T cells for enhanced anti-tumor efficacy. Dr. Chung's research focuses on harnessing synthetic biology to reprogram T cell differentiation states for cancer immunotherapy. Her laboratory employs protein engineering, next-generation sequencing, CRISPR screening, and bioinformatics to develop three core platforms: (1) Transcription factor recipes for T cell programming using multiomics atlas-based analysis and in vivo CRISPR screening; (2) Synthetic toolkits for designer immunity including drug-inducible transcription factor circuits and signal rewiring platforms; (3) Hijacking tumors via engineered oncolytic viruses to encode immune modulators. Her work aims to create context-specific cell state programming that enhances T cell therapy efficacy across diverse cancer types. Her publication portfolio demonstrates significant contributions to synthetic immunology, with high-impact papers in Science, Nature Chemical Biology, Cell, and Immunity covering protease-based control systems, T cell differentiation engineering, and tumor microenvironment remodeling. Recent work includes developing sonogenetic CAR-T cells controllable by ultrasound and elucidating metabolic mechanisms of T cell exhaustion. K01 Research Scientist Development Award, NIH, 2023 Keystone Symposia Future of Science Fund Scholarship, 2020 Damon Runyon Fellowship Award, 2019 Salk Women & Science Special Award, 2019 Hans Neurath Outstanding Promise Travel Award, 2017 Dr. Chung leads the Chung Lab at the UNC Lineberger Comprehensive Cancer Center, where she directs research on synthetic T cell engineering. Her lab utilizes advanced techniques including single-cell CRISPR screening, protein engineering, and oncolytic virology to develop next-generation immunotherapies. Current projects focus on creating artificial T cell differentiation pathways and engineering the tumor microenvironment to support persistent anti-tumor immunity.
Heather R. Christofk is a Professor in the Department of Biological Chemistry at the David Geffen School of Medicine at UCLA. Her research focuses on the intricate relationship between cellular metabolism and various biological processes, particularly in the contexts of cancer development, stem cell function, and viral infections. Education: PhD in Cell and Developmental Biology from Harvard University (2007) BS in Molecular, Cell, and Developmental Biology from UCLA (2001) Dr. Christofk's research program centers on understanding how metabolic pathways regulate cellular processes in both normal physiology and disease states. Her laboratory has made significant contributions to understanding how cancer cells reprogram their metabolism to support rapid growth and proliferation, with particular focus on glucose metabolism, amino acid utilization, and metabolic adaptations in tumor microenvironments. She has also pioneered work on the metabolic regulation of stem cell function, especially in hair follicle stem cells, demonstrating how metabolic pathways control stem cell activation and differentiation. Her research has important implications for developing novel therapeutic approaches that target cancer metabolism while preserving normal tissue function. Analysis of Dr. Christofk's recent publications reveals a strong focus on metabolic heterogeneity across different biological contexts. Her work spans cancer metabolism (particularly in liposarcoma, melanoma, and hepatocellular carcinoma), stem cell metabolism (especially hair follicle stem cells), viral metabolism (including Epstein-Barr virus and Zika virus), and developmental metabolism (fetal development and organogenesis). A recurring theme is how metabolic pathways serve as regulatory nodes that control cell fate decisions, tumor progression, and therapeutic responses. Selected Research Funding: Metabolic Control of Hair Follicle Stem Cell Homeostasis and Tumorigenesis (NIH R01AR070245, 2018-2023) - Co-Principal Investigator Nutrient regulation of cancer cell growth (NIH R01CA215185, 2017-2022) - Principal Investigator Regulation of the Warburg Effect in Cancer (NIH DP2OD008454, 2011-2016) - Principal Investigator Dr. Christofk's laboratory maintains active collaborations across multiple disciplines, working with clinicians, basic scientists, and computational biologists to address complex questions in metabolism and disease. Her team employs a range of cutting-edge techniques including metabolomics, stable isotope tracing, molecular biology, and in vivo models to investigate metabolic regulation in health and disease.
Professor Luke Lairson leads the Lairson Laboratory at The Scripps Research Institute (TSRI), focusing on chemical biology to study cell fate mechanisms in disease. His work spans small molecule discovery targeting cancer stem cells, tumor microenvironment modulation, and myelination enhancement using primary human and rodent cell models. Education: PhD in Chemistry (2007, University of British Columbia), BS in Biochemistry (2002, University of Guelph). Professional roles include Assistant Professor at TSRI (2010–present), Principal Investigator at the Genomics Institute of the Novartis Research Foundation (2010–2011), and Director of High Throughput Discovery at California Institute for Biomedical Research (2016–2017). Research Interests: Chemical approaches to cancer immunotherapy, drug discovery for neurodegenerative diseases, and modulation of immune checkpoint proteins. Key projects include STING agonist development, HSP90 inhibitors, and metabolite-driven oligodendrocyte maturation. Publications: Over 50 peer-reviewed articles, including high-impact work in PNAS , Nature Chemical Biology , and Cancer Research . Recent focus areas include microbiota-derived STING activators and JAK-inhibitor immunotherapy combinations. Awards: Canadian Society for Chemistry Boehringer Ingelheim Thesis Award (2010), Royal Society Short Visit Award (2007), and multiple scholarships for organic chemistry innovation. Lab Activities: Integrates high-content screening, medicinal chemistry, and proteomics to identify mechanism-based therapies. Current initiatives include repurposing drugs for remyelination and developing non-nucleotide STING agonists for systemic cancer immunotherapy.
Dr. Zhengqing Hu is a tenured, full-time Professor in the Department of Otolaryngology – Head and Neck Surgery at Wayne State University School of Medicine. He holds joint appointments in the Department of Physiology/Cell Biology and has active research programs in stem cell-based hearing restoration. Dr. Hu's academic journey includes dual MD and PhD training in China, a second PhD at Karolinska Institute, Sweden, and postdoctoral work at the University of Virginia. Education : MD from Shanghai Medical University, PhD in neurotology from China, second PhD in cell replacement therapy at Karolinska Institute Grants : NIH R01, DoD grants, VA SPiRE, and Wayne State OVPR funding His research focuses on auditory synapse regeneration , epigenetic reprogramming for hair cell repair, and development of biological hearing restoration models . The Hu lab employs stem cell biology, in vitro and in vivo transplantation, advanced microscopy, and electrophysiology to investigate inner ear progenitor cell differentiation and neural integration. Recent publications highlight DNA demethylation strategies for hair cell regeneration and auditory neuron synaptogenesis. Dr. Hu serves on multiple NIH, VA, and international grant review panels. He teaches graduate courses in Stem Cell Biology , Molecular Physiology , and Cell Biology at Wayne State University, including directing the Embryonic Stem Cell Biology course. His lab's work aims to establish a Biological-EAR model for future hearing loss treatments.
Dr. Gary K. Owens is a Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia , with a secondary appointment in the Department of Medicine, Division of Cardiology. He serves as Director of the Robert M. Berne Cardiovascular Research Center and leads groundbreaking research on vascular smooth muscle cell (SMC) dynamics in atherosclerosis. His work challenges conventional paradigms about SMC roles in plaque stability and thromboembolic events. Primary Affiliation: University of Virginia Key Titles: Robert M. Beirne Professor of Cardiovascular Research, Professor, Director of CVRC Research Themes include: Cardiovascular Biology Atherosclerosis Pathogenesis Smooth Muscle Cell Plasticity Epigenetic Regulation Inflammatory Signaling Tumor Metastasis Mechanisms Publication Trends (2015–2024) reveal expertise in Nature Medicine and Circulation studies, focusing on SMC gene regulation (Klf4/Oct4), plaque stability, and cross-talk between vascular cells and tumors. His work demonstrates that SMCs account for >80% of advanced lesion cells and that Klf4 inhibition reduces metastasis by >70%. Lab Leadership includes mentoring PhD students Anita Salamon and Victoria Milosek , alongside senior scientists and postdocs. Collaborations span with Dr. Gwen Randolph (Washington University) and Dr. Rosey Kaplan (NIH) on IL1β signaling and metastasis.
George M. Church is a Professor of Genetics at Harvard Medical School and affiliated with MIT, where he directs PersonalGenomes.org, providing open-access genomic, environmental and trait data. His laboratory focuses on transformative technologies for reading and writing 3D/4D biological structures with attention to ethics, safety, and equitable access. Church has co-initiated major scientific initiatives including the BRAIN Initiative (2011) and multiple Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005). Church's research spans multiple cutting-edge domains including genome engineering, synthetic biology, aging reversal, and space genetics. His lab pioneered foundational methods for direct genome sequencing, molecular multiplexing and barcoding in 1984, leading to the first genome sequence in 1994. His innovations contributed to nearly all next-generation DNA sequencing methods and companies. Current research directions include machine learning for protein engineering, tissue reprogramming, organoids, gene therapy, and in situ 3D DNA/RNA/protein imaging. His work bridges fundamental biology with therapeutic applications across diverse fields from Alzheimer's disease to de-extinction biology. Church's recent publications reveal a remarkable breadth of scientific inquiry, spanning from fundamental genome editing techniques to applications in aging research, neuroscience, and space biology. His work increasingly integrates artificial intelligence with biological systems, as seen in papers on machine-guided cell-fate engineering and automation of systematic reviews with large language models. His research maintains a strong translational focus, with numerous papers addressing therapeutic applications in cancer immunotherapy, gene therapy, and diagnostics. The consistent theme across his diverse publications is the development and application of transformative technologies to address fundamental biological questions and medical challenges. National Academy of Sciences (NAS) membership National Academy of Engineering (NAE) membership Franklin Bower Laureate for Achievement in Science Co-initiator of the BRAIN Initiative (2011) Director of multiple NIH Centers for Excellence in Genomic Science (2004-2020) Church directs numerous research centers including the NIH-CEGS, Personal Genome Project (PGP), Lipper Center for Computational Genetics, and Wyss Institute Synthetic Biology center. His laboratory has trained PhD students across multiple Harvard and MIT programs including Biophysics, BBS, Biomedical Informatics, ChemBio, Chemistry, SSQB, MCO, Virology, HST, EE/CS, Physics and Applied Math. His commercial impact is extensive through companies spanning medical diagnostics (Knome/PierianDx, Alacris, Nebula, Veritas) and synthetic biology/therapeutics (AbVitro/Juno, Gen9/enEvolv/Zymergen/Warpdrive/Gingko, Editas, Egenesis). Church also pioneered new privacy, biosafety, ELSI, environmental and biosecurity policies. The Church Lab operates across multiple research domains including molecular multiplexing, next-generation sequencing, nanopore technology, and genome engineering. The lab maintains strong connections with the Personal Genome Project, Wyss Institute, and multiple commercial ventures. Current research directions include the Spatial Atlas of Human Anatomy (SAHA), human skin rejuvenation via mRNA, and space genetics research through the Consortium for Space Genetics and BioAstra. The lab's mission focuses on transformative technologies for reading and writing 3D/4D structures at any scale, inspired by but not limited by biology.
